Parabilis Medicines, Inc.

Parabilis Medicines, Inc. (PBLS) priced its initial public offering on Jun 10, 2026 at $20.00 per share, raising $670M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.33B. Leerink Partners was lead-left underwriter, joined by BofA Securities, Evercore ISI and Guggenheim. Goodwin Procter advised the company and Covington & Burling advised the underwriters.

Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company developing Helicons, stabilized helical peptides engineered to bind and modulate protein targets long considered undruggable. Its lead product candidate is zolucatetide.

Status

IPO

Ticker

PBLS

Exchange

Nasdaq Global Select

Priced

Jun 10, 2026

IPO price

$20.00

Raised

$670M

Market cap at IPO price

$2.33B

First filed

May 19, 2026

Underwriters

Leerink Partners, BofA Securities, Evercore ISI and Guggenheim

Company counsel

Goodwin Procter

Underwriters' counsel

Covington & Burling

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.